Les angiotensines sont-elles liées à l'insuffisance cardiaque ?
Oui, des niveaux élevés d'angiotensines peuvent contribuer à l'insuffisance cardiaque.
AngiotensinesInsuffisance cardiaqueHypertension
#5
Quelles sont les conséquences d'une thérapie inappropriée des angiotensines ?
Une thérapie inappropriée peut aggraver l'hypertension et entraîner des complications graves.
AngiotensinesThérapieHypertension
Facteurs de risque
5
#1
Quels facteurs augmentent le risque d'hypertension liée aux angiotensines ?
L'obésité, le tabagisme et une alimentation riche en sodium augmentent le risque.
AngiotensinesHypertensionFacteurs de risque
#2
L'âge influence-t-il les niveaux d'angiotensines ?
Oui, le vieillissement peut augmenter la sensibilité aux angiotensines et l'hypertension.
AngiotensinesÂgeHypertension
#3
Le diabète est-il un facteur de risque pour les angiotensines ?
Oui, le diabète peut augmenter l'activité des angiotensines et le risque d'hypertension.
AngiotensinesDiabèteHypertension
#4
Le stress chronique influence-t-il les angiotensines ?
Oui, le stress chronique peut augmenter la production d'angiotensines et la pression artérielle.
AngiotensinesStressHypertension
#5
Les antécédents familiaux jouent-ils un rôle dans les angiotensines ?
Oui, des antécédents familiaux d'hypertension peuvent indiquer un risque accru d'angiotensines élevées.
AngiotensinesAntécédents familiauxHypertension
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Angiotensines : Questions médicales les plus fréquentes",
"headline": "Angiotensines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Angiotensines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-08",
"dateModified": "2026-06-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Angiotensines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Autacoïdes",
"url": "https://questionsmedicales.fr/mesh/D012898",
"about": {
"@type": "MedicalCondition",
"name": "Autacoïdes",
"code": {
"@type": "MedicalCode",
"code": "D012898",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.469.050"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Angiotensine-I",
"alternateName": "Angiotensin I",
"url": "https://questionsmedicales.fr/mesh/D000803",
"about": {
"@type": "MedicalCondition",
"name": "Angiotensine-I",
"code": {
"@type": "MedicalCode",
"code": "D000803",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.469.050.050.025"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Angiotensine-II",
"alternateName": "Angiotensin II",
"url": "https://questionsmedicales.fr/mesh/D000804",
"about": {
"@type": "MedicalCondition",
"name": "Angiotensine-II",
"code": {
"@type": "MedicalCode",
"code": "D000804",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.469.050.050.050"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Angiotensinamide",
"alternateName": "Angiotensin Amide",
"url": "https://questionsmedicales.fr/mesh/D000802",
"about": {
"@type": "MedicalCondition",
"name": "Angiotensinamide",
"code": {
"@type": "MedicalCode",
"code": "D000802",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.469.050.050.050.050"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Saralasine",
"alternateName": "Saralasin",
"url": "https://questionsmedicales.fr/mesh/D012504",
"about": {
"@type": "MedicalCondition",
"name": "Saralasine",
"code": {
"@type": "MedicalCode",
"code": "D012504",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.469.050.050.050.700"
}
}
},
{
"@type": "MedicalWebPage",
"name": "1-Sarcosyl-8-isoleucyl-angiotensine-II",
"alternateName": "1-Sarcosine-8-Isoleucine Angiotensin II",
"url": "https://questionsmedicales.fr/mesh/D015059",
"about": {
"@type": "MedicalCondition",
"name": "1-Sarcosyl-8-isoleucyl-angiotensine-II",
"code": {
"@type": "MedicalCode",
"code": "D015059",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.469.050.050.050.725"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Angiotensine-III",
"alternateName": "Angiotensin III",
"url": "https://questionsmedicales.fr/mesh/D000805",
"about": {
"@type": "MedicalCondition",
"name": "Angiotensine-III",
"code": {
"@type": "MedicalCode",
"code": "D000805",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.469.050.050.075"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Angiotensines",
"alternateName": "Angiotensins",
"code": {
"@type": "MedicalCode",
"code": "D000809",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "U Muscha Steckelings",
"url": "https://questionsmedicales.fr/author/U%20Muscha%20Steckelings",
"affiliation": {
"@type": "Organization",
"name": "Institute of Molecular Medicine, Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark (U.M.S.); Cardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, Victoria, Australia (R.E.W.); Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Republic of South Africa (E.D.S., L.L.); Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas (T.H.); Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute of Pharmacology, Cardiovascular-Metabolic-Renal (CMR) Research Center, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (E.K.); CARIM - School for Cardiovascular Diseases, Maastricht University, The Netherlands (T.U.); Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden (A.H.); Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia (R.M.C.); and Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida (C.S.) usteckelings@health.sdu.dk csumners@ufl.edu."
}
},
{
"@type": "Person",
"name": "Colin Sumners",
"url": "https://questionsmedicales.fr/author/Colin%20Sumners",
"affiliation": {
"@type": "Organization",
"name": "Institute of Molecular Medicine, Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark (U.M.S.); Cardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, Victoria, Australia (R.E.W.); Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Republic of South Africa (E.D.S., L.L.); Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas (T.H.); Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute of Pharmacology, Cardiovascular-Metabolic-Renal (CMR) Research Center, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (E.K.); CARIM - School for Cardiovascular Diseases, Maastricht University, The Netherlands (T.U.); Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden (A.H.); Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia (R.M.C.); and Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida (C.S.)."
}
},
{
"@type": "Person",
"name": "Michael Bader",
"url": "https://questionsmedicales.fr/author/Michael%20Bader",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Tahir Hussain",
"url": "https://questionsmedicales.fr/author/Tahir%20Hussain",
"affiliation": {
"@type": "Organization",
"name": "Institute of Molecular Medicine, Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark (U.M.S.); Cardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, Victoria, Australia (R.E.W.); Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Republic of South Africa (E.D.S., L.L.); Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas (T.H.); Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute of Pharmacology, Cardiovascular-Metabolic-Renal (CMR) Research Center, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (E.K.); CARIM - School for Cardiovascular Diseases, Maastricht University, The Netherlands (T.U.); Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden (A.H.); Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia (R.M.C.); and Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida (C.S.)."
}
},
{
"@type": "Person",
"name": "Thomas Unger",
"url": "https://questionsmedicales.fr/author/Thomas%20Unger",
"affiliation": {
"@type": "Organization",
"name": "Institute of Molecular Medicine, Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark (U.M.S.); Cardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, Victoria, Australia (R.E.W.); Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Republic of South Africa (E.D.S., L.L.); Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas (T.H.); Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute of Pharmacology, Cardiovascular-Metabolic-Renal (CMR) Research Center, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (E.K.); CARIM - School for Cardiovascular Diseases, Maastricht University, The Netherlands (T.U.); Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden (A.H.); Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia (R.M.C.); and Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida (C.S.)."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Decoding Angiotensin Receptors: TOMAHAQ-Based Detection and Quantification of Angiotensin Type-1 and Type-2 Receptors.",
"datePublished": "2023-09-08",
"url": "https://questionsmedicales.fr/article/37681524",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1161/JAHA.123.030791"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of renin-angiotensin inhibitors on renal function and the clinical course in patients with decompensated cirrhosis.",
"datePublished": "2023-10-14",
"url": "https://questionsmedicales.fr/article/37838780",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-44299-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of renin-angiotensin-aldosterone-system inhibitors on coronary atherosclerotic plaques: The PARADIGM registry.",
"datePublished": "2023-09-16",
"url": "https://questionsmedicales.fr/article/37769454",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.atherosclerosis.2023.117301"
}
},
{
"@type": "ScholarlyArticle",
"name": "Relationship between Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and the Risk of COVID-19: A Meta-Analysis.",
"datePublished": "2023-11-28",
"url": "https://questionsmedicales.fr/article/38058963",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2023/3431612"
}
},
{
"@type": "ScholarlyArticle",
"name": "CALU-3 lung cells three-dimensionally assembled onto CellFate® matrix present angiotensin-converting enzyme-2 activity.",
"datePublished": "2023-09-10",
"url": "https://questionsmedicales.fr/article/37691178",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/bit.28552"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Médiateurs de l'inflammation",
"item": "https://questionsmedicales.fr/mesh/D018836"
},
{
"@type": "ListItem",
"position": 4,
"name": "Autacoïdes",
"item": "https://questionsmedicales.fr/mesh/D012898"
},
{
"@type": "ListItem",
"position": 5,
"name": "Angiotensines",
"item": "https://questionsmedicales.fr/mesh/D000809"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Angiotensines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Angiotensines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-09-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Angiotensines",
"description": "Comment diagnostiquer une hyperactivité des angiotensines ?\nQuels symptômes indiquent un déséquilibre des angiotensines ?\nQuels examens sont utilisés pour évaluer les angiotensines ?\nLes angiotensines peuvent-elles être mesurées dans l'urine ?\nQuel rôle joue l'angiotensine dans l'hypertension ?",
"url": "https://questionsmedicales.fr/mesh/D000809#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Angiotensines",
"description": "Quels sont les symptômes d'une surproduction d'angiotensine ?\nComment l'angiotensine affecte-t-elle le cœur ?\nL'angiotensine peut-elle causer des maux de tête ?\nQuels signes indiquent une insuffisance rénale liée aux angiotensines ?\nL'angiotensine influence-t-elle l'appétit ?",
"url": "https://questionsmedicales.fr/mesh/D000809#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Angiotensines",
"description": "Comment prévenir les déséquilibres d'angiotensines ?\nL'hydratation influence-t-elle les angiotensines ?\nLe stress affecte-t-il les niveaux d'angiotensines ?\nQuels aliments aident à réguler les angiotensines ?\nL'exercice physique influence-t-il les angiotensines ?",
"url": "https://questionsmedicales.fr/mesh/D000809#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Angiotensines",
"description": "Quels médicaments ciblent les angiotensines ?\nComment les inhibiteurs de l'ECA agissent-ils ?\nLes diurétiques affectent-ils les niveaux d'angiotensines ?\nQuels effets secondaires des traitements anti-angiotensines ?\nPeut-on utiliser des remèdes naturels contre les angiotensines ?",
"url": "https://questionsmedicales.fr/mesh/D000809#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Angiotensines",
"description": "Quelles complications peuvent survenir avec des niveaux élevés d'angiotensines ?\nLes angiotensines peuvent-elles causer des maladies rénales ?\nComment l'angiotensine affecte-t-elle le système vasculaire ?\nLes angiotensines sont-elles liées à l'insuffisance cardiaque ?\nQuelles sont les conséquences d'une thérapie inappropriée des angiotensines ?",
"url": "https://questionsmedicales.fr/mesh/D000809#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Angiotensines",
"description": "Quels facteurs augmentent le risque d'hypertension liée aux angiotensines ?\nL'âge influence-t-il les niveaux d'angiotensines ?\nLe diabète est-il un facteur de risque pour les angiotensines ?\nLe stress chronique influence-t-il les angiotensines ?\nLes antécédents familiaux jouent-ils un rôle dans les angiotensines ?",
"url": "https://questionsmedicales.fr/mesh/D000809#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une hyperactivité des angiotensines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux d'angiotensine II peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un déséquilibre des angiotensines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme l'hypertension, la rétention d'eau ou des maux de tête peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour évaluer les angiotensines ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analyses sanguines et des tests de fonction rénale sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les angiotensines peuvent-elles être mesurées dans l'urine ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests urinaires peuvent également évaluer les niveaux d'angiotensines."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'angiotensine dans l'hypertension ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'angiotensine II provoque la constriction des vaisseaux sanguins, augmentant la pression."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une surproduction d'angiotensine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent hypertension, œdème et fatigue excessive."
}
},
{
"@type": "Question",
"name": "Comment l'angiotensine affecte-t-elle le cœur ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner une hypertrophie cardiaque due à une pression artérielle élevée."
}
},
{
"@type": "Question",
"name": "L'angiotensine peut-elle causer des maux de tête ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'augmentation de la pression artérielle due à l'angiotensine peut provoquer des céphalées."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une insuffisance rénale liée aux angiotensines ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes incluent fatigue, œdème et diminution de la production d'urine."
}
},
{
"@type": "Question",
"name": "L'angiotensine influence-t-elle l'appétit ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut affecter l'appétit en modifiant l'équilibre hydrique et électrolytique."
}
},
{
"@type": "Question",
"name": "Comment prévenir les déséquilibres d'angiotensines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain avec une alimentation équilibrée et de l'exercice régulier."
}
},
{
"@type": "Question",
"name": "L'hydratation influence-t-elle les angiotensines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une bonne hydratation aide à réguler les niveaux d'angiotensines et la pression artérielle."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il les niveaux d'angiotensines ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut augmenter la production d'angiotensine, contribuant à l'hypertension."
}
},
{
"@type": "Question",
"name": "Quels aliments aident à réguler les angiotensines ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les aliments riches en potassium, comme les bananes, peuvent aider à équilibrer les niveaux."
}
},
{
"@type": "Question",
"name": "L'exercice physique influence-t-il les angiotensines ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut aider à réduire les niveaux d'angiotensine et la pression artérielle."
}
},
{
"@type": "Question",
"name": "Quels médicaments ciblent les angiotensines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inhibiteurs de l'ECA et les antagonistes des récepteurs de l'angiotensine sont utilisés."
}
},
{
"@type": "Question",
"name": "Comment les inhibiteurs de l'ECA agissent-ils ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils bloquent la conversion de l'angiotensine I en angiotensine II, réduisant la pression."
}
},
{
"@type": "Question",
"name": "Les diurétiques affectent-ils les niveaux d'angiotensines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils aident à réduire la rétention d'eau et peuvent diminuer l'activité des angiotensines."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires des traitements anti-angiotensines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure toux, hyperkaliémie et hypotension."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des remèdes naturels contre les angiotensines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes comme l'ail peuvent aider à réguler la pression artérielle."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des niveaux élevés d'angiotensines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent l'hypertension, les maladies cardiaques et les AVC."
}
},
{
"@type": "Question",
"name": "Les angiotensines peuvent-elles causer des maladies rénales ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surproduction d'angiotensines peut entraîner des lésions rénales chroniques."
}
},
{
"@type": "Question",
"name": "Comment l'angiotensine affecte-t-elle le système vasculaire ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle provoque une constriction des vaisseaux, augmentant le risque de maladies vasculaires."
}
},
{
"@type": "Question",
"name": "Les angiotensines sont-elles liées à l'insuffisance cardiaque ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés d'angiotensines peuvent contribuer à l'insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une thérapie inappropriée des angiotensines ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une thérapie inappropriée peut aggraver l'hypertension et entraîner des complications graves."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'hypertension liée aux angiotensines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, le tabagisme et une alimentation riche en sodium augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux d'angiotensines ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut augmenter la sensibilité aux angiotensines et l'hypertension."
}
},
{
"@type": "Question",
"name": "Le diabète est-il un facteur de risque pour les angiotensines ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut augmenter l'activité des angiotensines et le risque d'hypertension."
}
},
{
"@type": "Question",
"name": "Le stress chronique influence-t-il les angiotensines ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut augmenter la production d'angiotensines et la pression artérielle."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle dans les angiotensines ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'hypertension peuvent indiquer un risque accru d'angiotensines élevées."
}
}
]
}
]
}
Institute of Molecular Medicine, Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark (U.M.S.); Cardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, Victoria, Australia (R.E.W.); Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Republic of South Africa (E.D.S., L.L.); Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas (T.H.); Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute of Pharmacology, Cardiovascular-Metabolic-Renal (CMR) Research Center, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (E.K.); CARIM - School for Cardiovascular Diseases, Maastricht University, The Netherlands (T.U.); Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden (A.H.); Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia (R.M.C.); and Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida (C.S.) usteckelings@health.sdu.dk csumners@ufl.edu.
Institute of Molecular Medicine, Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark (U.M.S.); Cardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, Victoria, Australia (R.E.W.); Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Republic of South Africa (E.D.S., L.L.); Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas (T.H.); Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute of Pharmacology, Cardiovascular-Metabolic-Renal (CMR) Research Center, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (E.K.); CARIM - School for Cardiovascular Diseases, Maastricht University, The Netherlands (T.U.); Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden (A.H.); Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia (R.M.C.); and Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida (C.S.).
Institute of Molecular Medicine, Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark (U.M.S.); Cardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, Victoria, Australia (R.E.W.); Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Republic of South Africa (E.D.S., L.L.); Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas (T.H.); Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute of Pharmacology, Cardiovascular-Metabolic-Renal (CMR) Research Center, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (E.K.); CARIM - School for Cardiovascular Diseases, Maastricht University, The Netherlands (T.U.); Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden (A.H.); Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia (R.M.C.); and Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida (C.S.).
Institute of Molecular Medicine, Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark (U.M.S.); Cardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, Victoria, Australia (R.E.W.); Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Republic of South Africa (E.D.S., L.L.); Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas (T.H.); Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute of Pharmacology, Cardiovascular-Metabolic-Renal (CMR) Research Center, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (E.K.); CARIM - School for Cardiovascular Diseases, Maastricht University, The Netherlands (T.U.); Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden (A.H.); Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia (R.M.C.); and Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida (C.S.).
Institute of Molecular Medicine, Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark (U.M.S.); Cardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, Victoria, Australia (R.E.W.); Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Republic of South Africa (E.D.S., L.L.); Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas (T.H.); Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute of Pharmacology, Cardiovascular-Metabolic-Renal (CMR) Research Center, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (E.K.); CARIM - School for Cardiovascular Diseases, Maastricht University, The Netherlands (T.U.); Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden (A.H.); Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia (R.M.C.); and Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida (C.S.).
Institute of Molecular Medicine, Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark (U.M.S.); Cardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, Victoria, Australia (R.E.W.); Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Republic of South Africa (E.D.S., L.L.); Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas (T.H.); Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute of Pharmacology, Cardiovascular-Metabolic-Renal (CMR) Research Center, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (E.K.); CARIM - School for Cardiovascular Diseases, Maastricht University, The Netherlands (T.U.); Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden (A.H.); Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia (R.M.C.); and Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida (C.S.).
Institute of Molecular Medicine, Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark (U.M.S.); Cardiovascular Disease Program, Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, Victoria, Australia (R.E.W.); Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Republic of South Africa (E.D.S., L.L.); Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas (T.H.); Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute of Pharmacology, Cardiovascular-Metabolic-Renal (CMR) Research Center, DZHK (German Centre for Cardiovascular Research), Berlin, Germany (E.K.); CARIM - School for Cardiovascular Diseases, Maastricht University, The Netherlands (T.U.); Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden (A.H.); Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia (R.M.C.); and Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida (C.S.).
Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Comprehensive Rodent Metabolic Phenotyping Core, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Department of Biomedical Engineering, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Electronic address: jgrobe@mcw.edu.
Background The renin-angiotensin system plays a crucial role in human physiology, and its main hormone, angiotensin, activates 2 G-protein-coupled receptors, the angiotensin type-1 and type-2 receptor...
Patients with decompensated cirrhosis are at risk of developing acute kidney injury (AKI). Studies have suggested that inhibition of the Renin-Angiotensin System (RAS) has certain nephro- and hepatopr...
Inhibition of Renin-Angiotensin-Aldosterone-System (RAAS) has been hypothesized to improve endothelial function and reduce plaque inflammation, however, their impact on the progression of coronary ath...
We performed a prospective, multinational study consisting of a registry of patients without history of CAD, who underwent serial CCTAs. Patients using RAAS inhibitors were propensity matched to RAAS ...
Of 1248 patients from the registry, 299 RAAS inhibitor taking patients were matched to 299 RAAS inhibitor naïve patients. Over a mean interval of 3.9 years, there was no significant difference in annu...
The use of RAAS inhibitors over a period of nearly 4 years did not significantly impact on total atherosclerotic plaque progression or various plaque components. However, interaction testing to assess...
Research shows the correlation between angiotensin-converting enzyme (ACE) deletion and insertion (D/I) polymorphism and COVID-19 risk; yet, conclusive evidence is still lacking. Thus, a meta-analysis...
The meta-analysis eventually contained 8 studies, including 1362 COVID-19 cases and 4312 controls. Based on the data, the ACE I/D polymorphism did not show an association with COVID-19 risk (D vs. I: ...
The ACE D allele was clearly related to an enhanced risk of COVID-19 severity. Hence, it is imperative to take into account the influence of genetic factors during the development of future vaccines....
Currently, there is a great need for the development of three-dimensional (3D) in vitro lung models. Particularly, the production of a suitable 3D model of pulmonary epithelium for understanding the p...
Systematic exercise training effectively improves exercise capacity in patients with coronary artery disease (CAD), but the magnitude of improvements is highly heterogeneous. We investigated whether t...
Concern exists regarding the renal safety of blocking the renin-angiotensin system (RAS) during acute illness, especially in the presence of volume depletion and hemodynamic instability....
We explored the impact of loop diuretics and RAS blockers on the likelihood of developing acute kidney injury (AKI) or acute kidney functional recovery (AKR) among inpatients. Adjusted odds ratio for ...
53,289 patients were included. RAS blockade was associated with reduced adjusted odds ratio for both AKI (0.76, CI 0.70-0.83) AKR (0.55, 0.52-0.58), and mortality within 30 days (0.44, 0.41-0.48), whe...
Reduced blood pressure, RAS blockers and diuretics affect the odds of developing AKI or AKR among inpatients, suggesting possible disruption in renal functional reserve (RFR). As long as blood pressur...
Angiotensin-converting enzyme 1 (ACE1) is a peptide involved in fluid and blood pressure management. It regulates blood pressure by converting angiotensin I to angiotensin II, which has vasoconstricti...
The present paper aims to characterize the Angiotensin-converting enzyme (ACE) genotype, with particular emphasis on its association with arterial oxygen saturation, arterial blood pressure, hemoglobi...
A cross-sectional sample of 168Monpa participants from Tawang town, Arunachal Pradesh, India, was selected who live at an altitude of ∼3,200 meters (m) above sea level. For each participant, height, w...
Unlike high-altitude natives from Peru and Ladakh, who exhibit high frequencies of II homozygotes, the Tawang Monpa shows a significantly high frequency of ID heterozygotes (p<0.0001). In addition, no...
The results suggest that the association of the ACE gene with resting SaO2 is inconsistent across native populations living under hypobaric hypoxia. Further, ACE I/D gene polymorphism may not be under...